This NDC is on FDA's drug shortage list (posted Oct 12, 2022)

Reported reason: Shortage of an active ingredient

Product Information

DEXTROAMP-AMPHETAMIN 30 MG TAB is a generic product labeled by Oryza Pharmaceuticals Inc., priced at $0.2900 per EA under NDC 72516001101. Its NADAC has been published 280 times since Mar 24, 2021.

FDA first approved this application on Apr 3, 2020. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

DEA Schedule CII

Strength

7.5; 7.5; 7.5; 7.5 mg/1; mg/1; mg/1; mg/1

NDC

72516001101

Classification

Generic

Dosage Form

TABLET

Route

ORAL

Effective Date

10/21/2026

Approval Type

Generic (ANDA)

FDA Application

ANDA210293

FDA Approved

4/3/2020

TE Code

AB

On Market Since

10/19/2020

Pharmacological Classes

Central Nervous System Stimulant
Central Nervous System Stimulant
Central Nervous System Stimulant
Central Nervous System Stimulant
Central Nervous System Stimulation
Central Nervous System Stimulation
Central Nervous System Stimulation
Central Nervous System Stimulation

Price Statistics

The NADAC for DEXTROAMP-AMPHETAMIN 30 MG TAB has been published 280 times since Mar 24, 2021, and over the history we have for it it has declined 29.2%. The table below summarizes its recorded NADAC range and movement.

Current price$0.2900 per EA
All-time high$0.4093 (Apr 14, 2021)
All-time low$0.2416 (Jul 17, 2024)
52-week high$0.3153
52-week low$0.2900
Median price$0.3124
Average price$0.3157
Largest weekly change-26.9% (Nov 20, 2024)
Weeks tracked280
Tracking sinceMar 24, 2021

Price History

1W

0.0%

1M

-1.9%

3M

-4.3%

6M

-5.1%

1Y

-4.5%

3Y

-11.3%

5Y

-20.8%

All

-29.2%

Generic Alternatives

The matcher finds 6 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Continue researching this drug

Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.

Frequently asked questions

What is the NADAC price of DEXTROAMP-AMPHETAMIN 30 MG TAB?

The current National Average Drug Acquisition Cost (NADAC) for DEXTROAMP-AMPHETAMIN 30 MG TAB, manufactured by Oryza Pharmaceuticals Inc., is $0.2900 per EA (NDC 72516001101), effective Nov 11, 2026.

How has the price of DEXTROAMP-AMPHETAMIN 30 MG TAB changed over time?

Over the history we have for it, the NADAC for DEXTROAMP-AMPHETAMIN 30 MG TAB has declined 29.2%. It has been tracked across 280 weekly CMS publications since Mar 24, 2021.

What are the highest and lowest recorded NADAC prices for DEXTROAMP-AMPHETAMIN 30 MG TAB?

Since Mar 24, 2021, the NADAC for DEXTROAMP-AMPHETAMIN 30 MG TAB has ranged from a low of $0.2416 (Jul 17, 2024) to a high of $0.4093 (Apr 14, 2021), with a median of $0.3124 per EA.

Are there cheaper alternatives to DEXTROAMP-AMPHETAMIN 30 MG TAB?

6 manufacturers publish a NADAC-priced product with the same active ingredient and strength as DEXTROAMP-AMPHETAMIN 30 MG TAB in a comparable dosage form, but none are currently priced below it.

Who manufactures DEXTROAMP-AMPHETAMIN 30 MG TAB?

DEXTROAMP-AMPHETAMIN 30 MG TAB (NDC 72516001101) is labeled by Oryza Pharmaceuticals Inc., and CMS classifies it as a generic product.

Is DEXTROAMP-AMPHETAMIN 30 MG TAB in shortage?

Yes — NDC 72516001101 is currently listed in FDA's drug shortage database (posted Oct 12, 2022). Reported reason: Shortage of an active ingredient.